Eli Lilly joins SNM imaging network

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 5
Volume 19
Issue 5

Eli Lilly has joined SNM’s Clinical Trials Network, a collaborative effort designed to address the need for validated imaging biomarkers for streamlining the development and registration of investigational therapeutics.

Eli Lilly has joined SNM's Clinical Trials Network, a collaborative effort designed to address the need for validated imaging biomarkers for streamlining the development and registration of investigational therapeutics.

The network also applies for and holds FDA new drug applications that will be available for cross-reference in multicenter clinical trials of imaging agents to assess response to treatment or to stratify patients for enrollment in clinical trials. "Eli Lilly seeks to improve patient outcomes by accelerating our therapeutic pipeline by using molecular imaging," said Johannes Tauscher, MD, a medical fellow and head of the translational imaging group at the company.

Recent Videos
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
2 experts are featured in this series.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.